Evidence map›Paper›PMID 36580481›Full record

ArticleThe Journal of infectious diseases2023

Investigation of Causal Effects of Protein Biomarkers on Cardiovascular Disease in Persons With HIV.

Cavan S Reilly, Álvaro H Borges, Jason V Baker, Sandra E Safo, Shweta Sharma, Mark N Polizzotto, James S Pankow, Xiaojun Hu, Brad T Sherman, Abdel G Babiker and 2 more

Open access · greenAbstract read
In one paragraph

Article in The Journal of infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 9 institutions in 4 countries.

Cavan S ReillyDivision of Biostatistics, University of Minnesota, Minneapolis, Minnesota, USA.
Álvaro H BorgesImmunology, Statens Serum Institut, Copenhagen, Denmark.
Jason V BakerHIV Medicine, Infectious Diseases, Hennepin County Medical Center, Minneapolis, Minnesota, USA.
Sandra E SafoDivision of Biostatistics, University of Minnesota, Minneapolis, Minnesota, USA.
Shweta SharmaDivision of Biostatistics, University of Minnesota, Minneapolis, Minnesota, USA.
Mark N PolizzottoDepartment of Medicine, Australian National University, Canberra, Australia.
James S PankowDivision of Epidemiology and Community Health, University of Minnesota, Minneapolis, Minnesota, USA.
Xiaojun HuAnimal and Plant Inspection Service, US Department of Agriculture, Beltsville, Maryland, USA.
Brad T ShermanLaboratory of Human Retrovirology and Immunoinformatics, Frederick National Laboratories, Frederick, Maryland, USA.
Abdel G BabikerEpidemiology and Medical Statistics, University College London, London, United Kingdom.
Jens D LundgrenDepartment of Infectious Diseases, University of Copenhagen, Copenhagen, Denmark.
H Clifford LaneDivision of Clinical Research, National Institutes of Allergy and Infectious Diseases, Bethesda, Maryland, USA.ORCID 0000-0001-9509-1045
University of Minnesota · USAnimal and Plant Health Inspection Service · USAustralian National University · AUFrederick National Laboratory for Cancer Research · USHennepin County Medical Center · USNational Institute of Allergy and Infectious Diseases · USStatens Serum Institut · DKUniversity College London · GBUniversity of Copenhagen · DK

Funding

Extended follow-up of randomized participants in the INSIGHT START trialU01AI136780 · NIAID · UNIVERSITY OF MINNESOTA · PI GRUND, BIRGIT, REILLY, CAVAN S. · 2019 to 2024
$18.0M
CCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001ENIAID NIH HHS U01 AI136780NIH HHS HHSN261200800001E
6 · The paper itself

Abstract

backgroundThere is an incompletely understood increased risk for cardiovascular disease (CVD) among people with HIV (PWH). We investigated if a collection of biomarkers were associated with CVD among PWH. Mendelian randomization (MR) was used to identify potentially causal associations.

methodsData from follow-up in 4 large trials among PWH were used to identify 131 incident CVD cases and they were matched to 259 participants without incident CVD (controls). Tests of associations between 460 baseline protein levels and case status were conducted.

resultsUnivariate analysis found CLEC6A, HGF, IL-6, IL-10RB, and IGFBP7 as being associated with case status and a multivariate model identified 3 of these: CLEC6A (odds ratio [OR] = 1.48, P = .037), HGF (OR = 1.83, P = .012), and IL-6 (OR = 1.45, P = .016). MR methods identified 5 significantly associated proteins: AXL, CHI3L1, GAS6, IL-6RA, and SCGB3A2.

conclusionsThese results implicate inflammatory and fibrotic processes as contributing to CVD. While some of these biomarkers are well established in the general population and in PWH (IL-6 and its receptor), some are novel to PWH (HGF, AXL, and GAS6) and some are novel overall (CLEC6A). Further investigation into the uniqueness of these biomarkers in PWH and the role of these biomarkers as targets among PWH is warranted.

Indexed as

Cardiovascular DiseasesHIV InfectionsBiomarkersHumansInterleukin-6Risk FactorsBiomarkersInterleukin-6fibrosisinflammationmendelian randomization

Identifiers

PMID36580481
PMCPMC10319949
OpenAlexW4313278738

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.